Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Teradyne, Inc. (TER) Price & Performance

Baxter International IncTrade
Teradyne, Inc.Trade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Teradyne, Inc. — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Teradyne, Inc. trades at $387.2 (market cap $57.08B). The key difference: Teradyne, Inc. is far larger — about 4× Baxter International Inc's market cap, and Baxter International Inc is trading nearer its 52-week high, Teradyne, Inc. nearer its low. Which is the better fit depends on your goals.

BAXTER
Market Cap
$14.36B$57.08B
Sector
HealthTechnology
52-Week High
$28.35$483.84
52-Week Low
$15.80$109.30
Enterprise Value
$21.88B$56.83B
Dividend Yield
0.14%0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.

Teradyne, Inc.

Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.

Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Teradyne, Inc.

Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.

Read more on TER